Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) has announced the appointment of Anil Singhal, Ph.D., President and CEO of Trishula Therapeutics, to its board of directors. Dr. Singhal brings over 30 years of oncology research and development leadership experience to HOWL's board. He previously served as President and CEO of Adicet Bio, where he led the company to its first oncology IND submission and merger with resTOR bio.

The appointment coincides with the planned resignation of Derek DiRocco from the board, effective at the company's 2025 annual meeting of stockholders. DiRocco has served on the board since joining during the Series B funding round led by RA Capital in 2020.

Werewolf Therapeutics focuses on developing conditionally activated therapeutics using its PREDATOR protein engineering platform to stimulate the immune system for treating cancer and immunological diseases.

Positive

• Addition of experienced executive with 30+ years of oncology R&D leadership
• Strengthening of board expertise in biopharmaceutical development and clinical trials
• Maintained continuity in board transition with planned resignation announcement

Negative

• None.

News Market Reaction

-2.90%

1 alert

-2.90% News Effect

On the day this news was published, HOWL declined 2.90%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors.

“I am thrilled to join Werewolf’s board of directors as the company advances its novel INDUKINE molecules through clinical development,” said Dr. Singhal. “Werewolf is demonstrating the power of the PREDATOR^TM protein engineering platform and its potential to provide safer and more efficacious treatments for cancer and immunological diseases.”

“I am pleased to welcome Dr. Singhal to our board of directors at this exciting time for our company,” added Luke Evnin, Ph.D., Chairman of the Board of Directors and co-founder of Werewolf Therapeutics. “With over 30 years of oncology research and development leadership and execution, Dr. Singhal’s proven experience represents a critical addition to our board’s skill set.”

Dr. Singhal joins the board of Werewolf Therapeutics with over three decades of research and development experience in the biopharmaceutical industry. Dr. Singhal is the President and Chief Executive Officer of Trishula Therapeutics, Inc., a private biotechnology company. Prior to that, Dr. Singhal served as the President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., where he led the then-private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc. Dr. Singhal is a member of the American Association of Cancer Research and a member of the American Society of Clinical Oncology. Dr. Singhal received his B.Sc Honours degree in Biochemistry from Panjab University in India, his MBA in Business Administration from the University of Washington and his Ph.D. in Biochemistry from Rutgers University.

Concurrent with the appointment of Dr. Singhal, Werewolf announced that Derek DiRocco plans to resign as a director of the Company, effective as of the Company’s 2025 annual meeting of stockholders. Dr. DiRocco has been a very valuable member of the Werewolf board since joining at the Series B raise led by RA Capital in 2020, and the Company appreciates his years of representation and support.

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR^® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.

FAQ

Who is the new board member appointed to Werewolf Therapeutics (HOWL)?

Dr. Anil Singhal, current President and CEO of Trishula Therapeutics, has been appointed to Werewolf Therapeutics' board of directors.

What experience does Dr. Singhal bring to HOWL's board?

Dr. Singhal brings over 30 years of oncology research and development leadership experience, including previous roles as President and CEO of Adicet Bio, where he led the company to its first oncology IND submission.

Who is leaving Werewolf Therapeutics' board in 2025?

Derek DiRocco will resign as a director at the company's 2025 annual meeting of stockholders. He has served since joining during the Series B funding round in 2020.

What is Werewolf Therapeutics' (HOWL) main technology platform?

Werewolf Therapeutics utilizes the PREDATOR protein engineering platform to develop conditionally activated therapeutics for cancer and immunological diseases.